PROK looking good at 2.00The potential is there. May be just under 4 level target. Both volume and price action is there.
Next report date
Report period
Q1 2024
EPS estimate
−0.29USD
Revenue estimate
—
−0.57USD
−35.47 MUSD
43.34 M
About ProKidney Corp.
Sector
Industry
CEO
Bruce Culleton
Website
Headquarters
Winston-Salem
Employees (FY)
163
Founded
2015
FIGI
BBG0119BQ2Y2
ProKidney Corp. is a clinical-stage biotechnology company, which engages in the development of a proprietary cell therapy platform. The firm focuses on the treatment of chronic kidney disease, shifting the emphasis away from management of kidney failure to the restoration of kidney function to stop or delay progression of CKD. It offers REACT, a product candidate that includes selected renal cells prepared from a patient's own, autologous, and renal cells. The company was founded on December 21, 2015 and is headquartered in Winston-Salem, NC.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of PROK is 2.30 USD — it has increased by 8.49% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange ProKidney Corp. stocks are traded under the ticker PROK.
ProKidney Corp. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
PROK stock is 15.74% volatile and has beta coefficient of 1.62. Check out the list of the most volatile stocks — is ProKidney Corp. there?
PROK earnings for the last quarter are −0.18 USD per share, whereas the estimation was −0.16 USD resulting in a −14.02% surprise. The estimated earnings for the next quarter are −0.14 USD per share. See more details about ProKidney Corp. earnings.
Yes, you can track ProKidney Corp. financials in yearly and quarterly reports right on TradingView.
PROK stock has risen by 14.43% compared to the previous week, the month change is a 46.50% rise, over the last year ProKidney Corp. has showed a 76.51% decrease.
PROK net income for the last quarter is −5.70 M USD, while the quarter before that showed −10.98 M USD of net income which accounts for 48.10% change. Track more ProKidney Corp. financial stats to get the full picture.
No, PROK doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, PROK shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ProKidney Corp. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 29, 2024, the company has 163.00 employees. See our rating of the largest employees — is ProKidney Corp. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ProKidney Corp. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ProKidney Corp. stock shows the sell signal. See more of ProKidney Corp. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ProKidney Corp. future price: according to them, PROK price has a max estimate of 6.00 USD and a min estimate of 2.00 USD. Read a more detailed ProKidney Corp. forecast: see what analysts think of ProKidney Corp. and suggest that you do with its stocks.